NextCure — Third Quarter 2026 Earnings Summary

NextCure has advanced its proposed merger with Avere Therapeutics, supported by approximately $820 million in committed financing from a syndicate of investors. The SEC declared the merger's registration statement effective on November 6, 2026, with a stockholder vote scheduled for December 9, 2026. During the third quarter of 2026, NextCure reported a net loss of $6.8 million and reduced its cash reserves to $8.7 million while executing restructuring initiatives and transferring the LNCB74 program to LigaChem. Upon completion of the merger, the combined entity will operate as Avere and trade on Nasdaq under the ticker symbol AVRX.